Market Place
Sourcing Support
Bright Peak Therapeutic Present Data at 2024 Annual Meeting of SITC
08 Nov 2024 //
GLOBENEWSWIRE
Bright Peak Doses First Patient In Phase 1/2a Trial Of BPT567
17 Oct 2024 //
GLOBENEWSWIRE
Bright Peak Therapeutics Announces $90 Million in Series C Financing
11 Jun 2024 //
GLOBENEWSWIRE
J&J-backed Bright Peak secures $90m to advance immunoconjugate programme
11 Jun 2024 //
PHARMACEUTICAL TECHNOLOGY
Bright Peak Presents Data at AACR 2024
09 Apr 2024 //
GLOBENEWSWIRE
Bright Peak Presents New Data at AACR: BPT567 A First-in-Class PD1-IL18
17 Apr 2023 //
GLOBENEWSWIRE
Bright Peak Presents New Therapeutics Highlighted by Multifunctional PD-1
09 Nov 2022 //
GLOBENEWSWIRE
Bright Peak to Present Innovative Multifunctional Regulatory T Cell Enhancers
20 Oct 2022 //
GLOBENEWSWIRE
Bright Peak Announces Formation of Immuno-Oncology Scientific Advisory Board
18 Oct 2022 //
GLOBENEWSWIRE
Bright Peak Announces the Appointment of Jon Wigginton as President of R&D
22 Aug 2022 //
GLOBENEWSWIRE
Bright Peak Announces Multiple Presentations at the AACR
04 Apr 2022 //
GLOBENEWSWIRE
Bright Peak Tx Appoints Leena Gandhi, M.D., Ph.D., to its Board of Directors
28 Feb 2022 //
GLOBENEWSWIRE
Bright Peak Therapeutics Licenses Rights to Livzon’s Anti-PD-1 Antibody LZM009
16 Nov 2021 //
GLOBENEWSWIRE
Bright Peak Therapeutics Announces $107 Million Series B Financing
10 Jun 2021 //
BUSINESSWIRE
Versant-backed Bright Peak sets a date to bring its IL-2 into the clinic
09 Jun 2021 //
ENDPTS
Ajinomoto, Bright Peak Enter Immunocytokines Research Pact
30 Mar 2021 //
CONTRACTPHARMA
Bright Peak Therapeutics Inc. & Ajinomoto Co., Inc. Enter into a Research
26 Mar 2021 //
GLOBENEWSWIRE
Bright Peak Therapeutics and Ajinomoto to create novel immunocytokines
25 Mar 2021 //
BIOSPECTRUMASIA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.